The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs...
Read moreThe study shows selective tumor uptake of IL12-7NP2 and potent antitumor activity as single agent and in combination with immune checkpoint inhibitors. The product is well tolerated when administered to...
Read moreDario Neri, co-founder, CEO and CSO, is giving a lecture entitled “Antibody-cytokine fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications”. Please follow the link below for more information...
Read moreProf. Dario Neri (CEO and CSO), and Emanuele Puca (Investor Relations) will participate at the event to present Philogen and its programs to the financial community.
Dr. Covelli (CMO), Dr. Elia, Dr. Ravenni, and Dr. Nadal will participate at the event in Rome. The dermato-oncology team from St. Gallen will give a presentation entitled “Intralesional administration...
Read morePhilogen attends the SITC Annual Meeting in November 2022. Teresa Hemmerle, PhD, Senior Project Manager, to present an abstract entitled “Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes...
Read more